6998 — Genor Biopharma Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- HK$568.91m
- -HK$683.50m
- 10
- 42
- 26
- 11
Annual cashflow statement for Genor Biopharma Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -524 | -3,036 | -866 | -732 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 111 | 2,414 | 129 | -6.54 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 262 | -215 | 52.4 | 108 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -111 | -787 | -624 | -578 | — |
| Capital Expenditures | -27.9 | -98.3 | -71.4 | -13 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -12.7 | 0.049 | 17.1 | 0.015 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -40.7 | -98.2 | -54.3 | -12.9 | — |
| Financing Cash Flow Items | -2.09 | -111 | -2.36 | -2.86 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 279 | 3,738 | 17.6 | -57.4 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 128 | 2,676 | -729 | -612 | — |